Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is designed to assess safety and effects of vorapaxar, when added to standard of care (aspirin and clopidigrel), in Japanese subjects with acute coronary syndrome. The study may also provide information about the effect of vorapaxar on preventing heart attack and stroke in this subject population.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Aspirin; Clopidogrel; Vorapaxar

Criteria

Inclusion Criteria:

• Men and women aged 18 years or more with history of cardiac ischemia related chest discomfort of > 10 minutes duration < 24 hours prior to randomization, and having at least 1 of the following A or B. Participants who are planned to undergo PCI will be the target participants.

• A: Positive biomarkers [Elevated troponin I or creatinine kinase MB isozyme greater than the site's upper limit of normal (ULN)] at or before registration

• B: Electrocardiogram (ECG) changes: ST segment depression >= 0.1 mV (>=1 mm), or transient (<30 minutes) ST segment elevation >= 0.1 mV (>=1 mm) in at least 2 contiguous leads

• Willing to give appropriate informed consent and complete all study-related procedures, and able to adhere to dosing and all visit schedules.

• Women of child-bearing potential (all postmenarchal women who are <1 years menopausal or who have not had surgical sterilization or a hysterectomy are considered to be women of child-bearing potential) must agree to use a medically accepted method of contraception while receiving protocol-specified medication, and for 60 days after stopping the medication.

Exclusion Criteria:

• Pregnant and nursing mothers (premenopausal women should have a negative pregnancy test result confirmed before enrollment)

• Any serious illness or any condition that the investigator feels would pose a significant hazard to the participant if investigational therapy were initiated

• known hypersensitivity to any component of the current investigational product;

• Participation in a study of experimental therapy or use of any investigational drug within 30 days before enrollment

• Member of the staff personnel directly involved with this study;

• Family member of the investigational study staff;

• History of a bleeding diathesis, or evidence of active abnormal bleeding within 30 days before enrollment

• History of a hemorrhagic stroke at any time

• Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) while receiving therapy;

• Major surgery within 2 weeks prior to enrollment

• Known platelet count <100,000/mm^3

• Uncontrolled cardiac arrhythmia;

• Known impairment of renal function (serum creatinine >2.0 mg/dL [>176.8 umol/L]), dysproteinemia, nephrotic syndrome, or other renal disease;

• Active or chronic hepatobiliary or hepatic disease, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) activity more than two times greater than the upper limit of the laboratory reference range

• Anticipated staged PCI

• Concurrent or anticipated treatment with warfarin, factor Xa inhibitor, direct thrombin inhibitor, or antiplatelet agents except aspirin and ticlopidine after enrollment

• Anticipated intracoronary brachytherapy